Neuilly-sur-Seine, France, November 15, 2018
ISIN Code : FR0013233475
Market : Euronext Paris
(Article L. 233-8 II of the Commerce Code – Article 223-16 of the General Regulations of the AMF – French Financial Markets Authority)
|Date||Number of shares outstanding||Theoretical total number of voting
|Total number of voting rights
|October 31, 2018||13,367,217||13,367,217||13,333,076|
- The total number of voting right is calculated based on the total shares having voting rights, including shares held in treasury deprived of voting rights.
- The number of voting rights exercisable is calculated without taking into account the share that hold no voting rights.
Lysogene is a gene therapy company focused on the treatment of orphan diseases of the central nervous system (CNS). The company has built a unique capability to enable a safe and effective delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A pivotal clinical trial in MPS IIIA in partnership with Sarepta Therapeutics, Inc. and a phase 1-2 clinical trial in GM1 Gangliosidosis are in preparation. In accordance with the agreements signed between Lysogene and Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc. will hold exclusive commercial rights to LYS-SAF302 in the United States and markets outside Europe, and Lysogene will maintain commercial exclusivity of LYS-SAF302 in Europe. Lysogene is also collaborating with a major partner to define the strategy of development for the treatment of Fragile X syndrome, a genetic disease related to autism. www.lysogene.com.
|Julie Coulot / Emmanuel Huynh|
|NewCap / + 33 1 44 71 94 94|